PHA-022121 for acute treatment and prophylaxis of angioedema attacks in acquired C1-inhibitor deficiency

Phase 2, randomised, double-blind trial of deucrictibant in C1 inhibitor deficiency and angioedema (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in 3-symptom composite visual analogue scale score from pre-treatment to 4 hours post-treatment and Normalized number of investigator-confirmed angioedema attacks per month of exposure. Started Oct 2021; status: active, not recruiting.